

## ICMJE DISCLOSURE FORM

Date: 2022/1/25

Your Name: Xiaobin Shang

Manuscript Title: Safety and effectiveness of pembrolizumab combined with paclitaxel and cisplatin as neoadjuvant therapy followed by surgery for locally advanced resectable (stage III) esophageal squamous cell carcinoma: a study protocol for a prospective, single-arm, single-center, open-label, phase-II trial (Keystone-001)

Manuscript number (if known): \_\_\_\_\_

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the current manuscript only.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
<b>Time frame: Since the initial planning of the work</b>			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) <b>No time limit for this item.</b>	<input checked="" type="checkbox"/> None	<input checked="" type="checkbox"/> None
<b>Time frame: past 36 months</b>			
2	Grants or contracts from any entity (if not indicated in item #1 above).	<input type="checkbox"/> None	
3	Royalties or licenses	<input type="checkbox"/> None	<input type="checkbox"/> None
4	Consulting fees	<input type="checkbox"/> None	<input type="checkbox"/> None

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	<input type="checkbox"/> X <input type="checkbox"/> None	<input type="checkbox"/> X <input type="checkbox"/> None
6	Payment for expert testimony	<input type="checkbox"/> X <input type="checkbox"/> None	<input type="checkbox"/> X <input type="checkbox"/> None
7	Support for attending meetings and/or travel	<input type="checkbox"/> X <input type="checkbox"/> None	<input type="checkbox"/> X <input type="checkbox"/> None
8	Patents planned, issued or pending	<input type="checkbox"/> X <input type="checkbox"/> None	<input type="checkbox"/> X <input type="checkbox"/> None
9	Participation on a Data Safety Monitoring Board or Advisory Board	<input type="checkbox"/> X <input type="checkbox"/> None	<input type="checkbox"/> X <input type="checkbox"/> None
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	<input type="checkbox"/> X <input type="checkbox"/> None	<input type="checkbox"/> X <input type="checkbox"/> None
11	Stock or stock options	<input type="checkbox"/> X <input type="checkbox"/> None	<input type="checkbox"/> X <input type="checkbox"/> None
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	<input type="checkbox"/> X <input type="checkbox"/> None	<input type="checkbox"/> X <input type="checkbox"/> None
13	Other financial or non-financial interests	<input type="checkbox"/> X <input type="checkbox"/> None	<input type="checkbox"/> X <input type="checkbox"/> None

**Please summarize the above conflict of interest in the following box:**

None

**Please place an "X" next to the following statement to indicate your agreement:**

**XI certify that I have answered every question and have not altered the wording of any of the questions on this form.**

## ICMJE DISCLOSURE FORM

Date: 2022/1/25

Your Name: Gang Zhao

Manuscript Title: Safety and effectiveness of pembrolizumab combined with paclitaxel and cisplatin as neoadjuvant therapy followed by surgery for locally advanced resectable (stage III) esophageal squamous cell carcinoma: a study protocol for a prospective, single-arm, single-center, open-label, phase-II trial (Keystone-001)

Manuscript number (if known): \_\_\_\_\_

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the current manuscript only.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)	
<b>Time frame: Since the initial planning of the work</b>				
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) <b>No time limit for this item.</b>	__X__ None	__X__ None	
<b>Time frame: past 36 months</b>				
2	Grants or contracts from any entity (if not indicated in item #1 above).	__X__ None		
3	Royalties or licenses	__X__ None	__X__ None	
4	Consulting fees	__X__ None	__X__ None	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	<input type="checkbox"/> X <input type="checkbox"/> None	<input type="checkbox"/> X <input type="checkbox"/> None
6	Payment for expert testimony	<input type="checkbox"/> X <input type="checkbox"/> None	<input type="checkbox"/> X <input type="checkbox"/> None
7	Support for attending meetings and/or travel	<input type="checkbox"/> X <input type="checkbox"/> None	<input type="checkbox"/> X <input type="checkbox"/> None
8	Patents planned, issued or pending	<input type="checkbox"/> X <input type="checkbox"/> None	<input type="checkbox"/> X <input type="checkbox"/> None
9	Participation on a Data Safety Monitoring Board or Advisory Board	<input type="checkbox"/> X <input type="checkbox"/> None	<input type="checkbox"/> X <input type="checkbox"/> None
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	<input type="checkbox"/> X <input type="checkbox"/> None	<input type="checkbox"/> X <input type="checkbox"/> None
11	Stock or stock options	<input type="checkbox"/> X <input type="checkbox"/> None	<input type="checkbox"/> X <input type="checkbox"/> None
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	<input type="checkbox"/> X <input type="checkbox"/> None	<input type="checkbox"/> X <input type="checkbox"/> None
13	Other financial or non-financial interests	<input type="checkbox"/> X <input type="checkbox"/> None	<input type="checkbox"/> X <input type="checkbox"/> None

**Please summarize the above conflict of interest in the following box:**

None

**Please place an "X" next to the following statement to indicate your agreement:**

**XI certify that I have answered every question and have not altered the wording of any of the questions on this form.**

## ICMJE DISCLOSURE FORM

Date: 2022/1/25

Your Name: Fei Liang

Manuscript Title: Safety and effectiveness of pembrolizumab combined with paclitaxel and cisplatin as neoadjuvant therapy followed by surgery for locally advanced resectable (stage III) esophageal squamous cell carcinoma: a study protocol for a prospective, single-arm, single-center, open-label, phase-II trial (Keystone-001)

Manuscript number (if known): \_\_\_\_\_

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the current manuscript only.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
<b>Time frame: Since the initial planning of the work</b>			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) <b>No time limit for this item.</b>	<input checked="" type="checkbox"/> None	<input checked="" type="checkbox"/> None
<b>Time frame: past 36 months</b>			
2	Grants or contracts from any entity (if not indicated in item #1 above).	<input type="checkbox"/> None	
3	Royalties or licenses	<input type="checkbox"/> None	<input type="checkbox"/> None
4	Consulting fees	<input type="checkbox"/> None	<input type="checkbox"/> None

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	<input type="checkbox"/> X <input type="checkbox"/> None	<input type="checkbox"/> X <input type="checkbox"/> None
6	Payment for expert testimony	<input type="checkbox"/> X <input type="checkbox"/> None	<input type="checkbox"/> X <input type="checkbox"/> None
7	Support for attending meetings and/or travel	<input type="checkbox"/> X <input type="checkbox"/> None	<input type="checkbox"/> X <input type="checkbox"/> None
8	Patents planned, issued or pending	<input type="checkbox"/> X <input type="checkbox"/> None	<input type="checkbox"/> X <input type="checkbox"/> None
9	Participation on a Data Safety Monitoring Board or Advisory Board	<input type="checkbox"/> X <input type="checkbox"/> None	<input type="checkbox"/> X <input type="checkbox"/> None
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	<input type="checkbox"/> X <input type="checkbox"/> None	<input type="checkbox"/> X <input type="checkbox"/> None
11	Stock or stock options	<input type="checkbox"/> X <input type="checkbox"/> None	<input type="checkbox"/> X <input type="checkbox"/> None
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	<input type="checkbox"/> X <input type="checkbox"/> None	<input type="checkbox"/> X <input type="checkbox"/> None
13	Other financial or non-financial interests	<input type="checkbox"/> X <input type="checkbox"/> None	<input type="checkbox"/> X <input type="checkbox"/> None

**Please summarize the above conflict of interest in the following box:**

None

**Please place an "X" next to the following statement to indicate your agreement:**

**XI certify that I have answered every question and have not altered the wording of any of the questions on this form.**

## ICMJE DISCLOSURE FORM

Date: 2022/1/25

Your Name: Chen Zhang

Manuscript Title: Safety and effectiveness of pembrolizumab combined with paclitaxel and cisplatin as neoadjuvant therapy followed by surgery for locally advanced resectable (stage III) esophageal squamous cell carcinoma: a study protocol for a prospective, single-arm, single-center, open-label, phase-II trial (Keystone-001)

Manuscript number (if known): \_\_\_\_\_

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the current manuscript only.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
<b>Time frame: Since the initial planning of the work</b>			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) <b>No time limit for this item.</b>	<input checked="" type="checkbox"/> None	<input checked="" type="checkbox"/> None
<b>Time frame: past 36 months</b>			
2	Grants or contracts from any entity (if not indicated in item #1 above).	<input type="checkbox"/> None	
3	Royalties or licenses	<input type="checkbox"/> None	<input type="checkbox"/> None
4	Consulting fees	<input type="checkbox"/> None	<input type="checkbox"/> None

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	<input type="checkbox"/> X <input type="checkbox"/> None	<input type="checkbox"/> X <input type="checkbox"/> None
6	Payment for expert testimony	<input type="checkbox"/> X <input type="checkbox"/> None	<input type="checkbox"/> X <input type="checkbox"/> None
7	Support for attending meetings and/or travel	<input type="checkbox"/> X <input type="checkbox"/> None	<input type="checkbox"/> X <input type="checkbox"/> None
8	Patents planned, issued or pending	<input type="checkbox"/> X <input type="checkbox"/> None	<input type="checkbox"/> X <input type="checkbox"/> None
9	Participation on a Data Safety Monitoring Board or Advisory Board	<input type="checkbox"/> X <input type="checkbox"/> None	<input type="checkbox"/> X <input type="checkbox"/> None
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	<input type="checkbox"/> X <input type="checkbox"/> None	<input type="checkbox"/> X <input type="checkbox"/> None
11	Stock or stock options	<input type="checkbox"/> X <input type="checkbox"/> None	<input type="checkbox"/> X <input type="checkbox"/> None
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	<input type="checkbox"/> X <input type="checkbox"/> None	<input type="checkbox"/> X <input type="checkbox"/> None
13	Other financial or non-financial interests	<input type="checkbox"/> X <input type="checkbox"/> None	<input type="checkbox"/> X <input type="checkbox"/> None

**Please summarize the above conflict of interest in the following box:**

None
------

**Please place an "X" next to the following statement to indicate your agreement:**

**XI certify that I have answered every question and have not altered the wording of any of the questions on this form.**



## ICMJE DISCLOSURE FORM

Date: 2022/1/25

Your Name: Weihong Zhang

Manuscript Title: Safety and effectiveness of pembrolizumab combined with paclitaxel and cisplatin as neoadjuvant therapy followed by surgery for locally advanced resectable (stage III) esophageal squamous cell carcinoma: a study protocol for a prospective, single-arm, single-center, open-label, phase-II trial (Keystone-001)

Manuscript number (if known): \_\_\_\_\_

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the current manuscript only.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
<b>Time frame: Since the initial planning of the work</b>			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) <b>No time limit for this item.</b>	<input checked="" type="checkbox"/> None	<input checked="" type="checkbox"/> None
<b>Time frame: past 36 months</b>			
2	Grants or contracts from any entity (if not indicated in item #1 above).	<input type="checkbox"/> None	
3	Royalties or licenses	<input type="checkbox"/> None	<input type="checkbox"/> None
4	Consulting fees	<input type="checkbox"/> None	<input type="checkbox"/> None

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	<input type="checkbox"/> X <input type="checkbox"/> None	<input type="checkbox"/> X <input type="checkbox"/> None
6	Payment for expert testimony	<input type="checkbox"/> X <input type="checkbox"/> None	<input type="checkbox"/> X <input type="checkbox"/> None
7	Support for attending meetings and/or travel	<input type="checkbox"/> X <input type="checkbox"/> None	<input type="checkbox"/> X <input type="checkbox"/> None
8	Patents planned, issued or pending	<input type="checkbox"/> X <input type="checkbox"/> None	<input type="checkbox"/> X <input type="checkbox"/> None
9	Participation on a Data Safety Monitoring Board or Advisory Board	<input type="checkbox"/> X <input type="checkbox"/> None	<input type="checkbox"/> X <input type="checkbox"/> None
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	<input type="checkbox"/> X <input type="checkbox"/> None	<input type="checkbox"/> X <input type="checkbox"/> None
11	Stock or stock options	<input type="checkbox"/> X <input type="checkbox"/> None	<input type="checkbox"/> X <input type="checkbox"/> None
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	<input type="checkbox"/> X <input type="checkbox"/> None	<input type="checkbox"/> X <input type="checkbox"/> None
13	Other financial or non-financial interests	<input type="checkbox"/> X <input type="checkbox"/> None	<input type="checkbox"/> X <input type="checkbox"/> None

**Please summarize the above conflict of interest in the following box:**

None
------

**Please place an "X" next to the following statement to indicate your agreement:**

**XI certify that I have answered every question and have not altered the wording of any of the questions on this form.**

## ICMJE DISCLOSURE FORM

Date: 2022/1/25

Your Name: Liang Liu

Manuscript Title: Safety and effectiveness of pembrolizumab combined with paclitaxel and cisplatin as neoadjuvant therapy followed by surgery for locally advanced resectable (stage III) esophageal squamous cell carcinoma: a study protocol for a prospective, single-arm, single-center, open-label, phase-II trial (Keystone-001)

Manuscript number (if known): \_\_\_\_\_

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the current manuscript only.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)	
<b>Time frame: Since the initial planning of the work</b>				
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) <b>No time limit for this item.</b>	<input checked="" type="checkbox"/> None	<input checked="" type="checkbox"/> None	
<b>Time frame: past 36 months</b>				
2	Grants or contracts from any entity (if not indicated in item #1 above).	<input type="checkbox"/> None		
3	Royalties or licenses	<input type="checkbox"/> None	<input type="checkbox"/> None	
4	Consulting fees	<input type="checkbox"/> None	<input type="checkbox"/> None	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	<input type="checkbox"/> X <input type="checkbox"/> None	<input type="checkbox"/> X <input type="checkbox"/> None
6	Payment for expert testimony	<input type="checkbox"/> X <input type="checkbox"/> None	<input type="checkbox"/> X <input type="checkbox"/> None
7	Support for attending meetings and/or travel	<input type="checkbox"/> X <input type="checkbox"/> None	<input type="checkbox"/> X <input type="checkbox"/> None
8	Patents planned, issued or pending	<input type="checkbox"/> X <input type="checkbox"/> None	<input type="checkbox"/> X <input type="checkbox"/> None
9	Participation on a Data Safety Monitoring Board or Advisory Board	<input type="checkbox"/> X <input type="checkbox"/> None	<input type="checkbox"/> X <input type="checkbox"/> None
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	<input type="checkbox"/> X <input type="checkbox"/> None	<input type="checkbox"/> X <input type="checkbox"/> None
11	Stock or stock options	<input type="checkbox"/> X <input type="checkbox"/> None	<input type="checkbox"/> X <input type="checkbox"/> None
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	<input type="checkbox"/> X <input type="checkbox"/> None	<input type="checkbox"/> X <input type="checkbox"/> None
13	Other financial or non-financial interests	<input type="checkbox"/> X <input type="checkbox"/> None	<input type="checkbox"/> X <input type="checkbox"/> None

**Please summarize the above conflict of interest in the following box:**

None

**Please place an "X" next to the following statement to indicate your agreement:**

**XI certify that I have answered every question and have not altered the wording of any of the questions on this form.**

## ICMJE DISCLOSURE FORM

Date: 2022/1/25

Your Name: Runmei Li

Manuscript Title: Safety and effectiveness of pembrolizumab combined with paclitaxel and cisplatin as neoadjuvant therapy followed by surgery for locally advanced resectable (stage III) esophageal squamous cell carcinoma: a study protocol for a prospective, single-arm, single-center, open-label, phase-II trial (Keystone-001)

Manuscript number (if known): \_\_\_\_\_

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the current manuscript only.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
<b>Time frame: Since the initial planning of the work</b>			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) <b>No time limit for this item.</b>	__X__ None	__X__ None
<b>Time frame: past 36 months</b>			
2	Grants or contracts from any entity (if not indicated in item #1 above).	__X__ None	
3	Royalties or licenses	__X__ None	__X__ None
4	Consulting fees	__X__ None	__X__ None

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	<input type="checkbox"/> X <input type="checkbox"/> None	<input type="checkbox"/> X <input type="checkbox"/> None
6	Payment for expert testimony	<input type="checkbox"/> X <input type="checkbox"/> None	<input type="checkbox"/> X <input type="checkbox"/> None
7	Support for attending meetings and/or travel	<input type="checkbox"/> X <input type="checkbox"/> None	<input type="checkbox"/> X <input type="checkbox"/> None
8	Patents planned, issued or pending	<input type="checkbox"/> X <input type="checkbox"/> None	<input type="checkbox"/> X <input type="checkbox"/> None
9	Participation on a Data Safety Monitoring Board or Advisory Board	<input type="checkbox"/> X <input type="checkbox"/> None	<input type="checkbox"/> X <input type="checkbox"/> None
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	<input type="checkbox"/> X <input type="checkbox"/> None	<input type="checkbox"/> X <input type="checkbox"/> None
11	Stock or stock options	<input type="checkbox"/> X <input type="checkbox"/> None	<input type="checkbox"/> X <input type="checkbox"/> None
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	<input type="checkbox"/> X <input type="checkbox"/> None	<input type="checkbox"/> X <input type="checkbox"/> None
13	Other financial or non-financial interests	<input type="checkbox"/> X <input type="checkbox"/> None	<input type="checkbox"/> X <input type="checkbox"/> None

**Please summarize the above conflict of interest in the following box:**

None
------

**Please place an "X" next to the following statement to indicate your agreement:**

**XI certify that I have answered every question and have not altered the wording of any of the questions on this form.**

## ICMJE DISCLOSURE FORM

Date: 2022/1/25

Your Name: Xiaofeng Duan

Manuscript Title: Safety and effectiveness of pembrolizumab combined with paclitaxel and cisplatin as neoadjuvant therapy followed by surgery for locally advanced resectable (stage III) esophageal squamous cell carcinoma: a study protocol for a prospective, single-arm, single-center, open-label, phase-II trial (Keystone-001)

Manuscript number (if known): \_\_\_\_\_

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the current manuscript only.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
<b>Time frame: Since the initial planning of the work</b>			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) <b>No time limit for this item.</b>	<input checked="" type="checkbox"/> None	<input checked="" type="checkbox"/> None
<b>Time frame: past 36 months</b>			
2	Grants or contracts from any entity (if not indicated in item #1 above).	<input type="checkbox"/> None	
3	Royalties or licenses	<input type="checkbox"/> None	<input type="checkbox"/> None
4	Consulting fees	<input type="checkbox"/> None	<input type="checkbox"/> None

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	<input type="checkbox"/> X <input type="checkbox"/> None	<input type="checkbox"/> X <input type="checkbox"/> None
6	Payment for expert testimony	<input type="checkbox"/> X <input type="checkbox"/> None	<input type="checkbox"/> X <input type="checkbox"/> None
7	Support for attending meetings and/or travel	<input type="checkbox"/> X <input type="checkbox"/> None	<input type="checkbox"/> X <input type="checkbox"/> None
8	Patents planned, issued or pending	<input type="checkbox"/> X <input type="checkbox"/> None	<input type="checkbox"/> X <input type="checkbox"/> None
9	Participation on a Data Safety Monitoring Board or Advisory Board	<input type="checkbox"/> X <input type="checkbox"/> None	<input type="checkbox"/> X <input type="checkbox"/> None
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	<input type="checkbox"/> X <input type="checkbox"/> None	<input type="checkbox"/> X <input type="checkbox"/> None
11	Stock or stock options	<input type="checkbox"/> X <input type="checkbox"/> None	<input type="checkbox"/> X <input type="checkbox"/> None
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	<input type="checkbox"/> X <input type="checkbox"/> None	<input type="checkbox"/> X <input type="checkbox"/> None
13	Other financial or non-financial interests	<input type="checkbox"/> X <input type="checkbox"/> None	<input type="checkbox"/> X <input type="checkbox"/> None

**Please summarize the above conflict of interest in the following box:**

None

**Please place an "X" next to the following statement to indicate your agreement:**

**XI certify that I have answered every question and have not altered the wording of any of the questions on this form.**



## ICMJE DISCLOSURE FORM

Date: 2022/1/25

Your Name: Zhao Ma

Manuscript Title: Safety and effectiveness of pembrolizumab combined with paclitaxel and cisplatin as neoadjuvant therapy followed by surgery for locally advanced resectable (stage III) esophageal squamous cell carcinoma: a study protocol for a prospective, single-arm, single-center, open-label, phase-II trial (Keystone-001)

Manuscript number (if known): \_\_\_\_\_

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the current manuscript only.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
<b>Time frame: Since the initial planning of the work</b>			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) <b>No time limit for this item.</b>	<input checked="" type="checkbox"/> None	<input checked="" type="checkbox"/> None
<b>Time frame: past 36 months</b>			
2	Grants or contracts from any entity (if not indicated in item #1 above).	<input type="checkbox"/> None	
3	Royalties or licenses	<input type="checkbox"/> None	<input type="checkbox"/> None
4	Consulting fees	<input type="checkbox"/> None	<input type="checkbox"/> None

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	<input type="checkbox"/> X <input type="checkbox"/> None	<input type="checkbox"/> X <input type="checkbox"/> None
6	Payment for expert testimony	<input type="checkbox"/> X <input type="checkbox"/> None	<input type="checkbox"/> X <input type="checkbox"/> None
7	Support for attending meetings and/or travel	<input type="checkbox"/> X <input type="checkbox"/> None	<input type="checkbox"/> X <input type="checkbox"/> None
8	Patents planned, issued or pending	<input type="checkbox"/> X <input type="checkbox"/> None	<input type="checkbox"/> X <input type="checkbox"/> None
9	Participation on a Data Safety Monitoring Board or Advisory Board	<input type="checkbox"/> X <input type="checkbox"/> None	<input type="checkbox"/> X <input type="checkbox"/> None
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	<input type="checkbox"/> X <input type="checkbox"/> None	<input type="checkbox"/> X <input type="checkbox"/> None
11	Stock or stock options	<input type="checkbox"/> X <input type="checkbox"/> None	<input type="checkbox"/> X <input type="checkbox"/> None
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	<input type="checkbox"/> X <input type="checkbox"/> None	<input type="checkbox"/> X <input type="checkbox"/> None
13	Other financial or non-financial interests	<input type="checkbox"/> X <input type="checkbox"/> None	<input type="checkbox"/> X <input type="checkbox"/> None

**Please summarize the above conflict of interest in the following box:**

None
------

**Please place an "X" next to the following statement to indicate your agreement:**

**XI certify that I have answered every question and have not altered the wording of any of the questions on this form.**

## ICMJE DISCLOSURE FORM

Date: 2022/1/25

Your Name: Jie Yue

Manuscript Title: Safety and effectiveness of pembrolizumab combined with paclitaxel and cisplatin as neoadjuvant therapy followed by surgery for locally advanced resectable (stage III) esophageal squamous cell carcinoma: a study protocol for a prospective, single-arm, single-center, open-label, phase-II trial (Keystone-001)

Manuscript number (if known): \_\_\_\_\_

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the current manuscript only.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)	
<b>Time frame: Since the initial planning of the work</b>				
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) <b>No time limit for this item.</b>	<input checked="" type="checkbox"/> None	<input checked="" type="checkbox"/> None	
<b>Time frame: past 36 months</b>				
2	Grants or contracts from any entity (if not indicated in item #1 above).	<input type="checkbox"/> None		
3	Royalties or licenses	<input type="checkbox"/> None	<input type="checkbox"/> None	
4	Consulting fees	<input type="checkbox"/> None	<input type="checkbox"/> None	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	<input type="checkbox"/> X <input type="checkbox"/> None	<input type="checkbox"/> X <input type="checkbox"/> None
6	Payment for expert testimony	<input type="checkbox"/> X <input type="checkbox"/> None	<input type="checkbox"/> X <input type="checkbox"/> None
7	Support for attending meetings and/or travel	<input type="checkbox"/> X <input type="checkbox"/> None	<input type="checkbox"/> X <input type="checkbox"/> None
8	Patents planned, issued or pending	<input type="checkbox"/> X <input type="checkbox"/> None	<input type="checkbox"/> X <input type="checkbox"/> None
9	Participation on a Data Safety Monitoring Board or Advisory Board	<input type="checkbox"/> X <input type="checkbox"/> None	<input type="checkbox"/> X <input type="checkbox"/> None
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	<input type="checkbox"/> X <input type="checkbox"/> None	<input type="checkbox"/> X <input type="checkbox"/> None
11	Stock or stock options	<input type="checkbox"/> X <input type="checkbox"/> None	<input type="checkbox"/> X <input type="checkbox"/> None
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	<input type="checkbox"/> X <input type="checkbox"/> None	<input type="checkbox"/> X <input type="checkbox"/> None
13	Other financial or non-financial interests	<input type="checkbox"/> X <input type="checkbox"/> None	<input type="checkbox"/> X <input type="checkbox"/> None

**Please summarize the above conflict of interest in the following box:**

None

**Please place an "X" next to the following statement to indicate your agreement:**

**XI certify that I have answered every question and have not altered the wording of any of the questions on this form.**

## ICMJE DISCLOSURE FORM

Date: 2022/1/25

Your Name: Chuangui Chen

Manuscript Title: Safety and effectiveness of pembrolizumab combined with paclitaxel and cisplatin as neoadjuvant therapy followed by surgery for locally advanced resectable (stage III) esophageal squamous cell carcinoma: a study protocol for a prospective, single-arm, single-center, open-label, phase-II trial (Keystone-001)

Manuscript number (if known): \_\_\_\_\_

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the current manuscript only.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)	
<b>Time frame: Since the initial planning of the work</b>				
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) <b>No time limit for this item.</b>	<input checked="" type="checkbox"/> None	<input checked="" type="checkbox"/> None	
<b>Time frame: past 36 months</b>				
2	Grants or contracts from any entity (if not indicated in item #1 above).	<input type="checkbox"/> None		
3	Royalties or licenses	<input type="checkbox"/> None	<input type="checkbox"/> None	
4	Consulting fees	<input type="checkbox"/> None	<input type="checkbox"/> None	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	<input type="checkbox"/> X <input type="checkbox"/> None	<input type="checkbox"/> X <input type="checkbox"/> None
6	Payment for expert testimony	<input type="checkbox"/> X <input type="checkbox"/> None	<input type="checkbox"/> X <input type="checkbox"/> None
7	Support for attending meetings and/or travel	<input type="checkbox"/> X <input type="checkbox"/> None	<input type="checkbox"/> X <input type="checkbox"/> None
8	Patents planned, issued or pending	<input type="checkbox"/> X <input type="checkbox"/> None	<input type="checkbox"/> X <input type="checkbox"/> None
9	Participation on a Data Safety Monitoring Board or Advisory Board	<input type="checkbox"/> X <input type="checkbox"/> None	<input type="checkbox"/> X <input type="checkbox"/> None
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	<input type="checkbox"/> X <input type="checkbox"/> None	<input type="checkbox"/> X <input type="checkbox"/> None
11	Stock or stock options	<input type="checkbox"/> X <input type="checkbox"/> None	<input type="checkbox"/> X <input type="checkbox"/> None
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	<input type="checkbox"/> X <input type="checkbox"/> None	<input type="checkbox"/> X <input type="checkbox"/> None
13	Other financial or non-financial interests	<input type="checkbox"/> X <input type="checkbox"/> None	<input type="checkbox"/> X <input type="checkbox"/> None

**Please summarize the above conflict of interest in the following box:**

None
------

**Please place an "X" next to the following statement to indicate your agreement:**

**XI certify that I have answered every question and have not altered the wording of any of the questions on this form.**

## ICMJE DISCLOSURE FORM

Date: 2022/1/25

Your Name: Bin Meng

Manuscript Title: Safety and effectiveness of pembrolizumab combined with paclitaxel and cisplatin as neoadjuvant therapy followed by surgery for locally advanced resectable (stage III) esophageal squamous cell carcinoma: a study protocol for a prospective, single-arm, single-center, open-label, phase-II trial (Keystone-001)

Manuscript number (if known): \_\_\_\_\_

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the current manuscript only.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
<b>Time frame: Since the initial planning of the work</b>			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) <b>No time limit for this item.</b>	__X__ None	__X__ None
<b>Time frame: past 36 months</b>			
2	Grants or contracts from any entity (if not indicated in item #1 above).	__X__ None	
3	Royalties or licenses	__X__ None	__X__ None
4	Consulting fees	__X__ None	__X__ None

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	<input type="checkbox"/> X <input type="checkbox"/> None	<input type="checkbox"/> X <input type="checkbox"/> None
6	Payment for expert testimony	<input type="checkbox"/> X <input type="checkbox"/> None	<input type="checkbox"/> X <input type="checkbox"/> None
7	Support for attending meetings and/or travel	<input type="checkbox"/> X <input type="checkbox"/> None	<input type="checkbox"/> X <input type="checkbox"/> None
8	Patents planned, issued or pending	<input type="checkbox"/> X <input type="checkbox"/> None	<input type="checkbox"/> X <input type="checkbox"/> None
9	Participation on a Data Safety Monitoring Board or Advisory Board	<input type="checkbox"/> X <input type="checkbox"/> None	<input type="checkbox"/> X <input type="checkbox"/> None
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	<input type="checkbox"/> X <input type="checkbox"/> None	<input type="checkbox"/> X <input type="checkbox"/> None
11	Stock or stock options	<input type="checkbox"/> X <input type="checkbox"/> None	<input type="checkbox"/> X <input type="checkbox"/> None
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	<input type="checkbox"/> X <input type="checkbox"/> None	<input type="checkbox"/> X <input type="checkbox"/> None
13	Other financial or non-financial interests	<input type="checkbox"/> X <input type="checkbox"/> None	<input type="checkbox"/> X <input type="checkbox"/> None

**Please summarize the above conflict of interest in the following box:**

None

**Please place an "X" next to the following statement to indicate your agreement:**

**XI certify that I have answered every question and have not altered the wording of any of the questions on this form.**



## ICMJE DISCLOSURE FORM

Date: 2022/1/25

Your Name: Xiubao Ren

Manuscript Title: Safety and effectiveness of pembrolizumab combined with paclitaxel and cisplatin as neoadjuvant therapy followed by surgery for locally advanced resectable (stage III) esophageal squamous cell carcinoma: a study protocol for a prospective, single-arm, single-center, open-label, phase-II trial (Keystone-001)

Manuscript number (if known): \_\_\_\_\_

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the current manuscript only.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
<b>Time frame: Since the initial planning of the work</b>			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) <b>No time limit for this item.</b>	<input checked="" type="checkbox"/> None	<input checked="" type="checkbox"/> None
<b>Time frame: past 36 months</b>			
2	Grants or contracts from any entity (if not indicated in item #1 above).	<input type="checkbox"/> None	
3	Royalties or licenses	<input type="checkbox"/> None	<input type="checkbox"/> None
4	Consulting fees	<input type="checkbox"/> None	<input type="checkbox"/> None

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	<input type="checkbox"/> X <input type="checkbox"/> None	<input type="checkbox"/> X <input type="checkbox"/> None
6	Payment for expert testimony	<input type="checkbox"/> X <input type="checkbox"/> None	<input type="checkbox"/> X <input type="checkbox"/> None
7	Support for attending meetings and/or travel	<input type="checkbox"/> X <input type="checkbox"/> None	<input type="checkbox"/> X <input type="checkbox"/> None
8	Patents planned, issued or pending	<input type="checkbox"/> X <input type="checkbox"/> None	<input type="checkbox"/> X <input type="checkbox"/> None
9	Participation on a Data Safety Monitoring Board or Advisory Board	<input type="checkbox"/> X <input type="checkbox"/> None	<input type="checkbox"/> X <input type="checkbox"/> None
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	<input type="checkbox"/> X <input type="checkbox"/> None	<input type="checkbox"/> X <input type="checkbox"/> None
11	Stock or stock options	<input type="checkbox"/> X <input type="checkbox"/> None	<input type="checkbox"/> X <input type="checkbox"/> None
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	<input type="checkbox"/> X <input type="checkbox"/> None	<input type="checkbox"/> X <input type="checkbox"/> None
13	Other financial or non-financial interests	<input type="checkbox"/> X <input type="checkbox"/> None	<input type="checkbox"/> X <input type="checkbox"/> None

**Please summarize the above conflict of interest in the following box:**

None
------

**Please place an "X" next to the following statement to indicate your agreement:**

**XI certify that I have answered every question and have not altered the wording of any of the questions on this form.**

## ICMJE DISCLOSURE FORM

Date: 2022/1/25

Your Name: Hongjing Jiang

Manuscript Title: Safety and effectiveness of pembrolizumab combined with paclitaxel and cisplatin as neoadjuvant therapy followed by surgery for locally advanced resectable (stage III) esophageal squamous cell carcinoma: a study protocol for a prospective, single-arm, single-center, open-label, phase-II trial (Keystone-001)

Manuscript number (if known): \_\_\_\_\_

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the current manuscript only.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
<b>Time frame: Since the initial planning of the work</b>			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) <b>No time limit for this item.</b>	__X__ None	__X__ None
<b>Time frame: past 36 months</b>			
2	Grants or contracts from any entity (if not indicated in item #1 above).	__X__ None	
3	Royalties or licenses	__X__ None	__X__ None
4	Consulting fees	__X__ None	__X__ None

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	<input type="checkbox"/> X <input type="checkbox"/> None	<input type="checkbox"/> X <input type="checkbox"/> None
6	Payment for expert testimony	<input type="checkbox"/> X <input type="checkbox"/> None	<input type="checkbox"/> X <input type="checkbox"/> None
7	Support for attending meetings and/or travel	<input type="checkbox"/> X <input type="checkbox"/> None	<input type="checkbox"/> X <input type="checkbox"/> None
8	Patents planned, issued or pending	<input type="checkbox"/> X <input type="checkbox"/> None	<input type="checkbox"/> X <input type="checkbox"/> None
9	Participation on a Data Safety Monitoring Board or Advisory Board	<input type="checkbox"/> X <input type="checkbox"/> None	<input type="checkbox"/> X <input type="checkbox"/> None
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	<input type="checkbox"/> X <input type="checkbox"/> None	<input type="checkbox"/> X <input type="checkbox"/> None
11	Stock or stock options	<input type="checkbox"/> X <input type="checkbox"/> None	<input type="checkbox"/> X <input type="checkbox"/> None
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	<input type="checkbox"/> X <input type="checkbox"/> None	<input type="checkbox"/> X <input type="checkbox"/> None
13	Other financial or non-financial interests	<input type="checkbox"/> X <input type="checkbox"/> None	<input type="checkbox"/> X <input type="checkbox"/> None

**Please summarize the above conflict of interest in the following box:**

None
------

**Please place an "X" next to the following statement to indicate your agreement:**

**XI certify that I have answered every question and have not altered the wording of any of the questions on this form.**